169 related articles for article (PubMed ID: 1579329)
21. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary.
Peters WA; Smith MR; Cain JM; Lee RB; Yon JL
Gynecol Oncol; 1992 Nov; 47(2):146-9. PubMed ID: 1468691
[TBL] [Abstract][Full Text] [Related]
23. The long-term survival of women with surgical stage II endometrioid type endometrial cancer.
Ayhan A; Taskiran C; Celik C; Yuce K
Gynecol Oncol; 2004 Apr; 93(1):9-13. PubMed ID: 15047207
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma.
Soper JT; Johnson P; Johnson V; Berchuck A; Clarke-Pearson DL
Obstet Gynecol; 1992 Dec; 80(6):949-53. PubMed ID: 1333065
[TBL] [Abstract][Full Text] [Related]
25. The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy.
Signorelli M; Fruscio R; Ceppi L; Dell'anna T; Vitobello D; Chiappa V; Siesto G; Milani R; Landoni F; Mangioni C
Gynecol Oncol; 2014 Feb; 132(2):312-5. PubMed ID: 24423881
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals.
Creasman WT; Disaia PJ; Blessing J; Wilkinson RH; Johnston W; Weed JC
Am J Obstet Gynecol; 1981 Dec; 141(8):921-9. PubMed ID: 7315922
[TBL] [Abstract][Full Text] [Related]
27. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
28. Chromic phosphate therapy in carcinoma of the ovary.
Goodman A; Bornstein L; Ball H; Smith DM; Bankoff M
J Am Coll Surg; 1994 Oct; 179(4):401-6. PubMed ID: 7921388
[TBL] [Abstract][Full Text] [Related]
29. 32P following negative second-look laparotomy for epithelial ovarian cancer.
Rogers L; Varia M; Halle J; Freddo J; Qaqish B; O'Keefe T; Fowler W
Gynecol Oncol; 1993 Aug; 50(2):141-6. PubMed ID: 8375727
[TBL] [Abstract][Full Text] [Related]
30. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
31. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
32. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary.
Park JY; Jin KL; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2012 Apr; 125(1):80-6. PubMed ID: 22210469
[TBL] [Abstract][Full Text] [Related]
33. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
[TBL] [Abstract][Full Text] [Related]
34. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
[TBL] [Abstract][Full Text] [Related]
35. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
Vaccarello L; Rubin SC; Vlamis V; Wong G; Jones WB; Lewis JL; Hoskins WJ
Gynecol Oncol; 1995 Apr; 57(1):61-5. PubMed ID: 7705701
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
McGowan L
Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
[TBL] [Abstract][Full Text] [Related]
38. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis.
Zanetta G; Rota S; Chiari S; Bonazzi C; Bratina G; Torri V; Mangioni C
Ann Oncol; 1998 Oct; 9(10):1097-101. PubMed ID: 9834822
[TBL] [Abstract][Full Text] [Related]
39. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
Sornsukolrat S; Tuipae S
J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
